Chlorpheniramine: Clinical Trials

8 trials of Chlorpheniramine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated, 2 completed, 1 recruiting, 1 unknown. 8 Phase 2, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 28Terminated 3, Completed 2, Recruiting 1, Unknown 1, Withdrawn 1
Phase 33Completed 2, Withdrawn 1

Follow Chlorpheniramine: new trials by email Literature Review of Chlorpheniramine trials Research Report on Chlorpheniramine

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III
Chlorpheniramine Maleate 0.4% Nasal Spray, Placebo - COVID-19, Symptoms and Signs
Phase 2 / Phase 3CompletedDr. Ferrer BioPharma1572022-07-272023-06-02
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I
Chlorpheniramine Maleate 1% Nasal Spray, Placebo - COVID-19, Symptoms and Signs
Phase 2 / Phase 3CompletedDr. Ferrer BioPharma1012021-12-072023-03-23
Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.
Placebo, Chlorpheniramine - Allergic Transfusion Reaction
Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China66422021-01-012026-11-12
Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis
CPM, Placebo - Allergic Rhinitis, Nasal Congestion
Phase 2 / Phase 3WithdrawnLarkin Community Hospital2019-07-302023-10-16
Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn
SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg, 2 capsules Ibuprofen and 1 placebo, capsule Chlorpheniramine 4mg and 1 Placebo - Sunburn
Phase 2TerminatedSephoris Pharmaceuticals LLC802018-01-152019-09-27
Exploratory Study for Allergy Relief Onset
Chlorpheniramine maleate (BAY X002134), Placebo - Rhinitis, Allergic
Phase 2TerminatedBayer12016-05-072018-12-12
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
ARC-520, Placebo, entecavir - Hepatitis B, Chronic
Phase 2TerminatedArrowhead Pharmaceuticals582014-03-012026-01-13
StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study
PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg - Rhinitis, Seasonal, Allergic
Phase 2UnknownMagna Pharmaceuticals, Inc.1252014-03-012014-05-30

Conditions studied

COVID-19 (2)  ·  Coronavirus Infections (2)  ·  Rhinitis, Allergic (2)  ·  Signs and Symptoms (2)  ·  Hepatitis (1)  ·  Hepatitis B, Chronic (1)  ·  Nasal Obstruction (1)  ·  Rhinitis (1)  ·  Rhinitis, Allergic, Seasonal (1)  ·  Sunburn (1)

Sponsors

Dr. Ferrer BioPharma (2)  ·  Arrowhead Pharmaceuticals (1)  ·  Bayer (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)  ·  Larkin Community Hospital (1)  ·  Magna Pharmaceuticals, Inc. (1)  ·  Sephoris Pharmaceuticals LLC (1)

Countries

United States (3)  ·  Honduras (2)  ·  China (1)  ·  Hong Kong (1)  ·  Mauritius (1)

Top investigators

Bruce Given, MD (1)  ·  Gitanjali Petkar, M.D (1)  ·  Marcos A Sanchez-Gonzalez (1)  ·  Stephen J Pollard, MD (1)

Results publications

PMID 33712437